Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasms

abstract

  • The addition of buparlisib to carboplatin¬†+¬†paclitaxel was well tolerated, and preliminary activity was notable against tumors with loss of PTEN expression.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-015-2693-z

PubMed ID

  • 25672916

Additional Document Info

start page

  • 747

end page

  • 55

volume

  • 75

number

  • 4